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Abstract: Zika virus (ZIKV), one of the flaviviruses, has attracted worldwide attention since its
large epidemics around Brazil. Association of ZIKV infection with microcephaly and neurological
problems such as Guillain–Barré syndrome has prompted intensive pathological investigations.
However, there is still a long way to go on the discovery of effective anti-ZIKV therapeutics. In this
study, an in silico screening of the National Cancer Institute (NCI) diversity set based on ZIKV NS3
helicase was performed using a molecular docking approach. Selected compounds with drug-like
properties were subjected to cell-based antiviral assays resulting in the identification of two novel
lead compounds (named Compounds 1 and 2). They inhibited ZIKV infection with IC50 values at the
micro-molar level (8.5 µM and 15.2 µM, respectively). Binding mode analysis, absolute binding free
energy calculation, and structure–activity relationship studies of these two compounds revealed their
possible interactions with ZIKV NS3 helicase, suggesting a mechanistic basis for further optimization.
These two novel small molecules may represent new leads for the development of inhibitory drugs
against ZIKV.
Keywords: Zika virus; flaviviruses; structure-based virtual screening; non-structural protein 3;
benzenediol; tetrahydroxy pentanoate
1. Introduction
The rapid spread of Zika virus (ZIKV) infection has become a severe and escalating threat to
global health. ZIKV is a mosquito-borne pathogen and belongs to the genus Flavivirus of the family
Flaviviridae that includes Hepatitis C virus (HCV), Dengue virus (DENV), and West Nile virus (WNV).
ZIKV was first isolated in 1947 from a rhesus monkey around the Zika forest of Uganda [1]. However,
it has not been paid much attention until 2015, when it rapidly remerged in at least 33 countries and
territories [2,3], and became an expanding epidemic across Central and South America [4]. ZIKV
infection can cause common symptoms such as fever, headache, arthralgia, conjunctivitis, as well
as macular atrophy [5]. During 2015 and 2016, substantial evidence has confirmed its congenital,
perinatal, and sexual transmission [6,7], and noted that ZIKV infection is directly associated with
frightening neural diseases including Guillain–Barré syndrome [8] and congenital microcephaly [9].
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ZIKV can be transmitted from a mother to a developing fetus during pregnancy and therefore inflict
severe birth defect including fetal growth restriction, neurological and ocular abnormalities, or even
perinatal death [10]. This fast-emerging pandemic and the related severe clinical situations have
invigorated efforts to seek effective antiviral therapeutics against ZIKV for both prevention and
post-infection treatment.
ZIKV has a positive-sense single-stranded genomic RNA that encodes a single polyprotein
precursor consisting of both structural proteins and non-structural proteins (NSPs) from NS1 to NS5.
Three-dimensional structures of ZIKV NSPs including NS1 [11,12], NS2B-NS3 protease [13–15], NS3
helicase [16], NS5 methyltransferase [17–19], as well as NS5 RNA polymerase have been determined
consecutively [20]. They are cooperatively involved in viral polyprotein processing and RNA
synthesizing processes including RNA maturation, splicing, as well as nuclear export [21]. A major
component involved in the ZIKV replication complex is NS3, a multifunctional protein with an
N-terminal serine protease domain (NS3Pro) responsible for polyprotein processing, and a C-terminal
region that serves as an RNA helicase (NS3Hel) for viral replication [16,20]. ZIKV protease is a
two-component protease consisting of the N-terminal region of NS3 and the cytoplasmic region of
NS2B as its cofactor; they collaborate to position the catalytic triad to catalyze its substrate [22]. ZIKV
NS3Hel belongs to the helicase superfamily of nucleic acid-dependent NTPases and are capable
of unwinding DNA or RNA duplex substrates [23]. The crucial function of NS3Hel during viral
replication has made it a promising drug target for direct-acting antiviral agents (DAA) [24].
Discovery of a novel drug for antiviral therapy is often a time- and labor-consuming process [25,26].
To date, there are still very few successful cases in the development of clinically approved treatment
therapies for Zika virus infection, making the discovery of anti-ZIKV drugs an urgent task [4]. In recent
years, structure-based virtual (also known as in silico) screening has become a useful approach for
identifying potential lead compounds [27]. In silico screening is considered to be one of the rapid,
efficient, and cost-effective methods for screening a large set of compounds [28]. Such an approach has
been proven to be valuable in antiviral DAA discovery [29,30]. Indications from the development of
DAAs for other flaviviruses including DENV and WNV emphasized the strategy of blocking viral
enzymes [29,30]. Recent structural evidence has revealed molecular mechanisms of NS3 helicase
activity and accordingly provided precise information for the rational drug design of small molecule
inhibitors against ZIKV [14,16,22,31]. In this study, structure-based virtual screening on ZIKV NS3Hel
followed by antiviral biological assays was performed with the aim of discovering novel inhibitors.
2. Results
2.1. Structure-Based Virtual Screening of a Diverse Library
Crystal structures of ZIKV NS3 helicase in complex with single-stranded RNA (ssRNA) and
nucleoside triphosphate (NTP), respectively, have unveiled a molecular basis for RNA unwinding
activities [16,32,33]. ssRNA runs across the central groove of each domain with the bases stacked
against each other, while NTP binds the cleft between domains 1 and 2 [16,32,33]. Here, we performed
a virtual screening by docking small molecules from a compound library to ZIKV NS3Hel active
sites including both RNA and NTP binding cavities (Figure 1). The NCI diversity compound dataset
was derived from almost 250,000 compounds and the final set was selected using the programs
Chem-X (Oxford Molecular Group) and Catalyst (Accelrys, Inc., San Diego, CA, USA) using defined
pharmacophoric centers and distance intervals. A total of 1974 compounds with structural diversity
were used to perform the docking study. Docking scores of all compounds were presented by SYBYL
and 5% top-scoring compounds with a C_Score > 4.0 and a crash value > −2.0 were ruled out. Most of
them revealed interaction with three to five residues around the pocket primarily by forming hydrogen
bonds with both main and side chains on these amino acids. Further, a drug-likeness filter was set as
molecular weight from 200 to 500 g/mol, Log-P value from −2.00 to 5.00, number of hydrogen acceptors
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from 2 to 8, and donors from 0 to 5. Compounds in accordance with this filter were ordered from NCI
library of the Developmental Therapeutics Program of NCI/NIH.Molecules 2019, 24, x FOR PEER REVIEW 3 of 17 
 
 
Figure 1. Molecular demonstration of the docking modes generated according to the binding grooves 
of (A) single-stranded RNA (ssRNA) (protein data bank (PDB) ID: 5GJB, shown in spring green) and 
(B) nucleoside triphosphate (NTP) (PDB ID: 5GJC, shown in pink within Zika virus (ZIKV) non-
structural protein 3 helicase (NS3Hel) (shown in sky blue). 
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inhibitory potency against ZIKV infection. Eight of them (Table 1), designated as Compounds 1–8 
(NSC10580, ZINC01706300; NSC45741, ZINC263598830; NSC99676, ZINC100132692; NSC95910, 
ZINC1621537; NSC20172, ZINC2046417; NSC100297, ZINC00001260; NSC299209, ZINC1871679; 
NSC99799, ZINC2291012), assisted cell survival against viral infection as shown by cytopathic effect 
inhibition assay. They showed inhibitory activities of more than 20% at the concentration of 20 μM. 
Among these compounds tested, Compound 1 (NSC10580, ZINC01706300)—an amphipathic 
benzenediol structure—and Compound 2 (NSC45741, ZINC263598830)—a highly hydrophilic 
molecule—exhibited more than 50% inhibition on BHK-21 cell lines against ZIKV infection. Thus, 
these two compounds were selected as the leads for further investigation. We assessed their ability 
to reduce plaque formation during ZIKV in vitro infection. In the presence of Compound 1 or 
Compound 2, plaque formation of ZIKV was markedly reduced compared to the virus control group 
in the absence of drugs (Figure 2). Compound 1 at the concentration of 20 μM and Compound 2 at 
the concentration of 100 μM achieved significant plaque reduction. We further determined their IC50 
values against ZIKV infection. Both of them dose-dependently suppressed ZIKV-induced cytopathic 
effects, with IC50 values at a micro-molar level (8.5 μM and 15.2 μM, respectively) (Figure 3). IFN-α 
at 20 IU served as a positive control in all antiviral tests. Cytotoxicity studies of Compounds 1 and 2 
were further performed to confirm that there was no obvious toxicity on BHK-21 cell lines compared 
to DMSO-treated cells within the above dose range (Figure 4). 
Table 1. Initial compounds identified by structure-based virtual screening and antiviral evaluation. 
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structure, chemical properties, and experimental inhibitory activities. Inhibitory activities at 20 μM 
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Figure 1. Molecular demonstration of the docking modes generated according to the binding grooves
of (A) single-stranded RNA (ssRNA) (protein data bank (PDB) ID: 5GJB, shown in spring green) and (B)
nucleoside triphosphate (NTP) (PDB ID: 5GJC, shown in pink within Zika virus (ZIKV) non-structural
protein 3 helicase (NS3Hel) (shown in sky blue).
2.2. Antiviral Activity Against in Vitro ZIKV Infection
Subsequently, ordered compounds were tested on BHK-21 cell lines to determine their inhibitory
potency against ZIKV infection. Eight of them (Table 1), designated as Compounds 1–8 (NSC10580,
ZINC01706300; NSC45741, INC263598830; NSC99676, ZINC100 32692; NSC95910, ZINC1621537;
NSC20172, ZINC2 46417; NSC100297, 00001260; S 299209, ZINC187167 ; SC99799,
ZINC2291012), assisted cell survival against viral infection as shown by cytopathic effect inhibition
assay. They showed inhibitory activitie of more than 20% at the c centration of 20 µM. Among
these compounds tested, Compound 1 (NSC10580, ZINC0170630 )—an amphipathic benzenediol
structure—and Co pound 2 (NSC45741, ZINC263598830)—a highly hydrophilic molecule—exhibi ed
more than 50% inhibition on BHK-21 cell lines against ZIKV infection. Thus, these two comp unds
were selected as the leads for further invest ga . We assessed their ability to reduce plaque f rmation
during ZIKV in vitro infection. In he presenc of C mpound 1 or Comp und 2, plaqu formation of
ZIKV was markedly reduced compared to the virus co trol group in the absence drugs (Figure 2).
Compound 1 at the concentration of 20 µM nd Compound 2 at the concentration of 100 µM achieved
signific nt plaque reduction. W further determined ir IC50 values against ZIKV infection. Both of
them dos -dependently suppressed ZIKV-i duced cytopathic effects, with IC50 values at a micro-molar
level (8.5 µM and 15.2 µM, respectively) (Figure 3). IFN-α at 20 IU served as a positive control in all
antiviral tests. Cytotoxicity studies of Compounds 1 and 2 were furth r rformed to confirm that
there was no obvious t xicity on BHK-21 cell l nes compared to DMSO- reat d cells within the above
dose range (Figure 4).
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Table 1. Initial compounds identified by structure-based virtual screening and antiviral evaluation. Compounds presented by National Cancer Institute (NCI) ID,
ZINC ID, molecular name, 2D chemical structure, chemical properties, and experimental inhibitory activities. Inhibitory activities at 20 µM were evaluated by in vitro
ZIKV infection assay.
Compound No NCI ID, ZINC ID and Molecular Name Structure Molecular Weight(g/mol) Log-P Value
H-Bond Acceptor
Count
H-Bond Donor
Count
Inhibitory
Activities %
1
NSC10580
ZINC01706300
3-(1-piperidinylmethyl)-5-(1,1,3,3-
tetramethylbutyl)-1,2-benzenediol
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ZINC01706300 
-(1-piperidinylmethyl)-
5-(1,1,3,3-
tetramethylbutyl)-1,2-
benzenediol 
 
319.489 4.798 3 3 73.241 ± 
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2
NSC45741
ZINC263598830
5-(1,3-benzothiazol-2-yl)-2,3,4,5-
tetrahydroxypentanoate
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served as a negative control. 
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addition, while less or almost no suppression of viral activity was observed for either pre-treatment 
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potency when added after 16 hpi. These data indicated that both Compound 1 and Compound 2 had 
the potential to block viral replication process instead of viral binding or entry.  
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2.3. Potential Inhibition on Viral Replication Process
To further explore the inhibitory mechanism, a time-of-drug-addition experiment from
pre-treatment to 72 h post infection (hpi) was performed to investigate whether our hit compounds
blocked the stage of viral binding, entry, or replication during the infection cycle. Compound 1
and Compound 2 exerted high antiviral activities when administered during the first 8 h after virus
addition, while less or almost no suppression of viral activity was observed for either pre-treatment
or treatment from 0 hpi to 2 hpi (Figure 5). Both of two compounds started to lose their antiviral
potency when added after 16 hpi. These data indicated that both Compound 1 and Compound 2 had
the potential to block viral replication process instead of viral binding or entry.Molecules 2019, 24, x FOR PEER REVIEW 6 of 17 
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around the RNA binding cavity, indicating their potential to block the RNA unwinding reaction. 
Markedly, though both were predicted to block NS3Hel, two hit molecules demonstrated distinctive 
binding patterns inside the pocket. Compound 1 fulfilled the pockets near the interface of domains 1 
and 3. Hydroxyl groups on 1,2-benzenediol formed hydrogen bonds with side chains of Glu489 and 
Arg598 in opposite directions, while the nitrogen on the hexatomic ring projecting towards the side 
chain of Asp291. Piperidine ring on Compound 1 might act as a hydrophobic core by interacting with 
Pro292 (Figure 6A). Compound 2 was docked into the site within domain 2, with its side-chain 
hydroxyl groups forming hydrogen bonds with Thr290, Asp410, Ser452, and Arg456. The terminal 
carboxyl was surrounded by Thr449 and Asp481, therefore interrupting the original salt bridge and 
hydrogen bond between that is essential for RNA recognition and binding (Figure 6B). The two 
distinctive sites, designated Site A and Site B (Figure 6C), located respectively within the two clefts—
RNA entrance crevice and RNA exit crevice. They are both required for RNA unwinding [16,34]. 
Crystal structures of Zika virus helicase in recognizing its substrates indicated that residues Asp410 
and Arg598 could form hydrogen bonds with its substrate [32]. In particular, side chain of Asp410 in 
the inner core could form a salt bridge with residue Lys431 that is crucial for the binding of N3 atom 
of the adenine base. Its carbonyl oxygen also contributes multiple hydrogen bonds with the 2′-OH 
moieties from the ssRNA. Molecular docking results of Compounds 1 and 2 demonstrated highly 
competitive binding modes against the substrate binding site. 
Figure 5. Time-of-drug-addition assay of Compounds 1 and 2. (A) Inhibitory activities while treated
with Compound 1 under a concentration of 20 µM at various time points (from −2 to 0 h post infection
(hpi), from 0 to 2 hpi, at 0, 4, 8, 16, 24, 32, 48, and 72 hpi, respectively). (B) Inhibitory activities while
treated with Compound 2 under a concentration of 50 µM at the above time points.
2.4. Binding Modes and Interactions with NS3 in Silico
To understand potential modes of action for their inhibitory activities on ZIKV, we scrutinized the
in silico binding modes of these two compounds. Both Compounds 1 and 2 were docked into NS3Hel
pockets with favorable C_Scores and crash values and showed interaction with residues around the
R A binding cavity, indicating their potential to block the RNA unwinding reaction. Markedly, though
both were predicted to block NS3Hel, two hit molecules demonstrated distinctive binding patterns
inside the pocket. Compound 1 fulfilled the pockets near the interface of domains 1 and 3. Hydroxyl
groups on 1,2-benzenediol formed hydrogen bonds with side chains of Glu489 and Arg598 in opposite
directions, while the nitrogen on the hexatomic ring projecting towards the side chain of Asp291.
Piperidine ring on Compound 1 might act as a hydrophobic core by interacting with Pro292 (Figure 6A).
Compound 2 was docked into the site within domain 2, with its side-chain hydroxyl groups forming
hydrogen bonds with Thr290, Asp410, Ser452, and Arg456. The terminal carboxyl was surrounded
by Thr449 and Asp481, therefore interrupting the original salt bridge and hydrogen bond between
that is essential for RNA recognition and binding (Figure 6B). The two distinctive sites, designated
Site A and Site B (Figure 6C), located respectively within the two clefts—RNA entrance crevice and
RNA exit crevice. They are both required for RNA unwinding [16,34]. Crystal structures of Zika virus
helicase in recognizing its substrates indicated that residues Asp410 and Arg598 could form hydrogen
bonds with its substrate [32]. In particular, side chain of Asp410 in the inner core could form a salt
bridge with residue Lys431 that is crucial for the binding of N3 atom of the adenine base. Its carbonyl
oxygen also contributes multiple hydrogen bonds with the 2′-OH moieties from the ssRNA. Molecular
docking results of Compounds 1 and 2 demonstrated highly competitive binding modes against the
substrate binding site.
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the hypothesis of above molecular interactions with NS3 helicase (Figure 7). The binding free energy 
of Compound 1 was dramatically reduced by site mutation of Asp291 since the difference of Gibbs 
free energy corresponds to exponential changes in dissociation constant (KD) values, indicating the 
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also essentially affected the binding of Compound 1, consistent with the above docking analysis. For 
Compound 2, mutations on Thr290, Asp410, Arg456, and Asp481 reduced the absolute values of 
binding free energy in various degrees, demonstrating that these residues significantly contributed 
to ligand binding while residues including Thr449 and Ser452 had relatively less importance for 
affinity. This could, as well, be caused by conformational changes of the complex structure during 
molecular dynamics. The resulting absolute binding free energy also showed that Compound 1, in 
agreement with antiviral experiments, had a higher affinity (−14.09 Kcal/mol) than Compound 2 
(−8.05 Kcal/mol) to NS3 helicase. These theoretical calculations provided us quantitative evidence to 
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Figure 6. (A) Predicted binding modes of Compound 1 (shown in green with color by atom type)
inside ZIKV NS3Hel pocket w th crucial interacting residues (show in blue). (B) Predicted binding
modes of Compound 2 (shown in magenta with color by atom type) inside ZIKV NS3Hel pocket with
crucial interacting residues (shown in blue). (C) M lecul r demonstration of target sit A and site
B (shown in cyan and pink, re pectively) g nerated according to predicted interacting residues and
relative locations to ssRNA (shown in gray) inside ZIKV NS3Hel (shown in tan), orresponding to
RNA entry and exit path.
2.5. Absolute Binding Free Energy Calculation
Encouraged by our docking models, microscopic free energy calculation together with in silico
mutagenesis of residues that were observed in the binding modes was performed to further validate
the hypothesis of above molecular interactions with NS3 helicase (Figure 7). The binding free energy
of Compound 1 was dramatically reduced by site mutation of Asp291 since the difference of Gibbs
free energy corresponds to exponential changes in dissociation constant (KD) values, indicating the
relatively strong interaction between the hexatomic ring of Compound 1 and the side chain of Asp291.
Mutations on charged residues Glu489 and Arg598, as well as uncharged residue Pro292, also essentially
affected the binding of Compound 1, consistent with the above docking analysis. For Compound 2,
mutations on Thr290, Asp410, Arg456, and Asp481 reduced the absolute values of binding free energy
in various degrees, demonstrating that these residues significantly contributed to ligand binding while
residues including Thr449 and Ser452 had relatively less importance for affinity. This could, as well, be
caused by conformational changes of the complex structure during molecular dynamics. The resulting
absolute binding free energy also showed that Compound 1, in agreement with antiviral experiments,
had a higher affinity (−14.09 Kcal/mol) than Compound 2 (−8.05 Kcal/mol) to NS3 helicase. These
theoretical calculations provided us quantitative evidence to support our experimental and docking
data and inspiring insights to discuss ligand-target binding details.
Molecules 2019, 24, 1465 8 of 18Molecules 2019, 24, x FOR PEER REVIEW 8 of 17 
 
 
Figure 7. Absolute binding free energy values for two ligand–protein docking complexes using 
PDLD/S-LRA/β methodology. All energies are presented in Kcal/mol. (A) Calculated free energy of 
Compound 1 to NS3 helicase Wildtype (WT) and mutants (D291A, P292A, E489A, E489D, R598A, and 
R598K). (B) Calculated free energy of Compound 2 to NS3 helicase Wildtype (WT) and mutants 
(T290A, D410A, T449A, S452A, R456A, and D481A). 
2.6. Ligand-Based Search and Structure-Activity Relationship Analysis of Derivatives 
On the basis of the above antiviral activities and favorable binding modes, small-molecule 
compounds with scaffolds similar to those of Compound 1 and Compound 2 were examined for 
further structure-activity relationship (SAR) analysis (Table 2). Analogs available from the NCI 
compound database were ordered and evaluated by in vitro assay accordingly (Figure 8). Compound 
1A, bearing a morpholine instead of piperidine, exhibited a decrease in antiviral activity, indicating 
the role of the hydrophobic core in Compound 1 in its interaction with residue Pro292. Deletion of a 
phenolic hydroxyl group, presented in Compound 1B, or replacing it by alkyl chain, presented in 
Compound 1C, reduced the inhibitory activity as well, which was consistent with the potential 
interaction with residue Arg598 shown in the above analysis. Compounds 1D–F further indicated 
that either replacing piperidine by hydrophilic groups or shortening the alkyl chain resulted in a 
decrease in antiviral activity. For Compound 2, replacing the terminal carboxyl group with an 
alcoholic hydroxyl group in Compound 2A led to a lower activity. Further depletion or displacement 
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Figure 7. Absolute binding free energy values for two ligand–protein docking complexes using
PDLD/S-LRA/β methodology. All energies are presented in Kcal/mol. (A) Calculated free energy of
Compound 1 to NS3 helicase Wildtype (WT) and mutants (D291A, P292A, E489A, E489D, R598A, and
R598K). (B) Calculated free energy of Compound 2 to NS3 helicase Wildtype (WT) and mutants (T290A,
D410A, T449A, S452A, R456A, and D481A).
2.6. Ligand-Based Search and Structure-Activity Relationship Analysis of Derivatives
On the basis of the above antiviral activities a d favorable binding modes, small-molecule
compounds with scaffolds similar to those of Compound 1 and Compound 2 were examined for further
structure-activity relationship (SAR) analysis (Table 2). Analogs available from the NCI compound
database were ordered and evaluated by in vitro assay accordingly (Figure 8). Compound 1A, bearing
a morpholine instead of piperidine, exhibited a decrease in antiviral activity, indicating the role of
the hydrophobic core in Compound 1 in its interaction with residue Pro292. Deletion of a phenolic
hydroxyl group, presented in Compound 1B, or replacing it by alkyl chain, presented in Compound
1C, reduced the inhibitory activity as well, which was consistent with the potential interaction with
residue Arg598 shown in the above analysis. Compounds 1D–F further indicated that either replacing
piperidine by hydrophilic groups or shortening the alkyl chain resulted in a decrease in antiviral
activity. For Compound 2, replacing the terminal carboxyl group with an alcoholic hydroxyl group
in Compound 2A led to a lower activity. Further depletion or displacement of acidic groups, shown
in Compounds 2B and 2C, also demonstrated the interaction of those acidic chains with the protein
residues including Threonine, Arginine, and Aspartic acids as described above. Compounds 2D and
2E indicated that substitution of benzothiazole by benzimidazole might help increase the inhibitory
effect. Based on Compound 2E, we further found that introducing other hydrophobic groups such as
hexamethylene (Compound 2F) could also partly maintain the antiviral activity as was expected. The
above SAR analysis might shed light on further studies of binding patterns and modifications for these
two antiviral leads.
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Table 2. Derivative compounds identified by ligand-based search for SAR analysis and antiviral evaluation. Derivative compounds presented by NCI ID, ZINC ID,
molecular name, 2D chemical structure, chemical properties, and experimental inhibitory activities. Inhibitory activities at 20 µM (for Compound 1 and derivatives)
and 50 µM (for Compound 2 and derivatives) were evaluated by in vitro ZIKV infection assay.
Compound No NCI ID, ZINC ID and Molecular Name Structure Molecular Weight(g/mol) Log-P Value
H-bond Acceptor
Count
H-bond Donor
Count
Inhibitory
Activities %
1
NSC10580
ZINC01706300
3-(1-piperidinylmethyl)-5-
(1,1,3,3-tetramethylbutyl)- 1,2-benzenediol
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Table 1. Initial compounds identified by structure-based virtual screening and antiviral evaluation. 
Compounds presented by National Cancer Institute (NCI) ID, ZINC ID, molecular name, 2D chemical 
structure, chemical properties, and experimental inhibitory activities. Inhibitory activities at 20 μM 
were evaluated by in vitro ZIKV infection assay. 
Compound 
No 
NCI ID, ZINC ID and 
Molecular Name 
Structure 
Molecular 
Weight 
(g/mol) 
Log-P 
Value 
H-Bond 
Acceptor 
Count 
H-Bond 
Donor 
Count 
Inhibitory 
Activities 
% 
1 
NSC10580 
ZINC01706300 
3-(1-piperidinylmethyl)-
-(1,1,3,3-
tetramethylbutyl)-1,2-
benzenediol 
 
319.489 4.798 3 3 73.241 ± 
3.336 319.489 4.798 3 3 73.161 ± 2.363
1A
NSC10578
ZINC31613795
3-(morpholin-4-ylmethyl)-5-
(2,4,4-trimethylpentan-2-yl)benzene- 1,2-diol
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bis[(dimethylamino)me
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1F 
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ZINC610623 
4-tert-butyl-2,6-
bis[(dimethylamino)me
thyl]phenol  
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2 
NSC45741 
ZINC263598830 
5-(1,3-benzothiazol-2-
yl)-2,3,4,5-
tetrahydroxypentanoat
e 
 
321.279 −0.503 8 4 71.316 ± 
9.711 
2A 
NSC34443 
ZINC4777682 
1-(1,3-benzothiazol-2-
yl)pentane-1,2,3,4,5-
pentol 
 
285.314 −0.595 7 5 19.868 ± 
5.688 
2B 
NSC607001 
ZINC1609998 
1-(benzo[d]thiazol-2-
yl)-5-hydroxypentan-1-
one  
235.301 2.642 4 1 
14.238 ± 
2.179 
2C NSC38490 
ZINC1670696 
 
249.284 1.971 5 0 11.938 ± 
1.782 
321.461 3.644 4 2 42.602 ± 4.906
1B
NSC10650
ZINC1706378
2-(piperidin-1-ylmethyl)-4-
(2,4,4-trimethylpentan-2-yl)phenol
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Table 2. Cont.
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control. 
3. Discussion 
Increasing popularity of global travel, as well as the wider spread of mosquito vectors due to the 
climate change, has nowadays accelerated the transmission of flaviviruses including ZIKV. Its severe 
damage on both fetal and adult neural systems urged us to understand the pathological mechanism 
and find solution to block its infection. However, despite the urgency of fighting ZIKV, no vaccines 
or antiviral therapeutics have been approved clinically for combating ZIKV infection. Enzymatic 
proteins involved in viral replication and assembly have long been considered as crucial drug targets 
to develop therapeutic agents. Since 2015, several studies have reported results of high-throughput 
screening of compound libraries to find small molecules active against ZIKV infection using either a 
whole-virus assay [35,36] or protein-based assays [37–39]. A couple of hits or potential lead molecules 
were described, whereas others failed to act effectively against viral infection through exhibiting 
binding or inhibitory activity on the target enzymes [37]. 
Structural homology of ZIKV enzymatic proteins with those of other flaviviruses prompted the 
interest in previously reported molecules showing inhibition on HCV, DENV, WNV, and Japanese 
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3. Discussion
Increasing popularity of global travel, as well as the wider spread of mosquito vectors due to the
climate change, has now da s accelerated the transmission of flaviviruses including ZIKV. Its severe
damage on both fetal and adult neural systems urged us to understand the pathological mechanism
and find solution to block its infection. However, despite the urgency of fighting ZIKV, no vaccines
or antiviral therapeutics have been approved clinically for combating ZIKV infection. Enzymatic
proteins involved in viral replication and assembly have long been considered as crucial drug targets
to develop therapeutic agents. Since 2015, several studies have reported results of high-throughput
screening of compound libraries to find small molecules active against ZIKV infection using either a
whole-virus assay [35,36] or protein-based assays [ – ]. A couple of hits or potential lead molecules
were d scribed, whereas others failed to act effe l against viral infection throug exhibiting
binding or inhibitory activity on the target enzy ].
Structural homology of ZIKV enzy atic proteins with those of other flaviviruses prompted
the interest in previously reported molecules showing inhibition on HCV, DENV, WNV, and
Japanese Encephalitis Virus (JEV). Efforts were made to retest a portion of them, including protease
inhibitors [37,39,40] and RNA-dependent RNA polymerase inhibitors [38], to examine their potential
effects on ZIKV. Among the compounds tested, a couple of molecules could act against ZIKV with
IC50 values at a micro-molar level. Most of them, however, did not show an equal inhibitory activity
to their original target enzyme from HCV or other flaviviruses, which is understandable considering
the conformational flexibility, exposure to solvent, and slight sequential differences among these viral
proteins. Moreover, unlike the protease, few specific NS3 helicase/NTPase inhibitors have been reported
for flaviviruses [41–43]. So far, none of these flaviviral helicase inhibitors was efficaciously repurposed
to block ZIKV helicase. Therefore, our attention has been basically focused on this underexploited
target. Structural characterizations of ZIKV NS3Hel have been accomplished since 2016 [13,14,16,32,33],
providing insightful structural basis for rational drug design. Compared with those NS3Hel from
other flaviviruses, structures of ZIKV NS3Hel disclosed a similar core scaffold but variable loops—the
P loop (residues 196–203) and the RNA-binding loop (residues 244–255) [16], involved correspondingly
in the interaction of NS3Hel with 7-mer RNA and NTP. This underlined the necessity of finding novel
inhibitors for ZIKV NS3Hel.
Our drug discovery strategy here is a combinational workflow of virtual screening and antiviral
assessment to facilitate the discovering process of novel leads specifically targeting ZIKV. Previous
efforts on virtual screening of ZIKV inhibitors, to the best of our knowledge, have been focused on
NS2B-NS3 protease [44,45] and NS5 methyltransferase and RNA-dependent RNA polymerase [44,46,47].
Most of these studies were based on homology modeling instead of crystal structures or were not
evaluated by antiviral assays. Here, we selected a database of diverse chemical structures and two
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proven ligand-binding sites on ZIKV NS3Hel crystal structures with the aim of minimizing the screening
time and effort. We then assessed antiviral activity of best-docked molecules on a whole-virus assay and
found eight compounds exhibited anti-ZIKV potency. The two most potent compounds were further
selected as our lead compounds. Both of the two compounds dose-dependently inhibited ZIKV infection
in vitro, and therefore had potential for further in vivo and clinical studies. Besides the determination
of their antiviral activities and exploration of possible inhibitory mechanisms, a series of computational
analyses including molecular dynamics simulation, absolute binding free energy calculation, and SAR
analysis were performed to elucidate the potential mechanism of binding and inhibition.
Compound 1 is an amphipathic molecule bearing a benzenediol scaffold. Computer docking
simulations predicted the interaction with three polar residues of ZIKV NS3Hel and suggested its
possible blockade of the entrance cleft of RNA binding. Compound 2 exhibited a hydrophilic property
with a tetrahydroxy pentanoate structure. Predicted binding model indicted its potential to block the
exit cleft of RNA binding. Compound 2 was previously tested in a study of TRAIL pathway-specific
anticancer agents, yet no further biological application has been reported before [48].
Meanwhile, drug development is a long-term process involving significant effort, time, and
expense. Therefore, drug repurposing has been considered a viable, cost-effective, and efficient way
to speed up clinical application. It should be noted that Compound 7 (NSC100297, ZINC00001260)
reported here is a commercially used product, Dimetacrine, as an anti-depressive drug. It serves as an
antagonist targeting Acetylcholinesterase and reduces serine hydrolase activity [49,50]. In addition,
Compound 8 (NSC99799, ZINC22910125) is known to the market as Papaveroline, an alkaloid found
in opium. While the mechanism of pharmacological actions remains mostly unidentified, studies have
confirmed its inhibition on phosphodiesterase [51]. It remains to be seen whether further studies might
reveal any potential value of these existing drugs in a possible new use for treating ZIKV.
4. Conclusions
Wide spread of ZIKV and the associated severe neurological damage have prompted intensive
efforts to discover effective antiviral agents to fight this pandemic. With the aim of discovering novel
chemical structures targeting ZIKV infection, in this study we carried out virtual screening, antiviral
assays, and computational analyses to successfully identify two novel small molecules with anti-ZIKV
IC50 values of less than 20 µM. These two different chemical scaffolds are reported for the first time,
to our knowledge, to have anti-ZIKV activity and may represent promising leads for developing
anti-ZIKV agents. Compound 1 and Compound 2 showed competitive antiviral activity with IC50
values of 8.5 µM and 15.2 µM, respectively, and displayed specific inhibition against viral replication
processes. Predicted binding modes implied their potential to block the activity of NS3 RNA helicase
and lead to further investigation and optimization. Based on biological data and computational
insights, our study discovered two lead molecules with anti-ZIKV activity, paving the way for future
development of clinical therapeutics against ZIKV infection.
5. Materials and Methods
5.1. Hardware and Software
In silico studies were performed on Dell Workstation Precision 5810 with 2E5-2600 V3 2.133
GHz processor, 6 GB RAM, and 256 GB hard drive running in Red Hat Enterprise Linux (RHEL)
operating system. Bioinformatics software SYBYL-X 2.1.1 (Tripos Associates, St. Louis, MO, USA)
was used for virtual screening and docking simulations. MOLARIS package version 9.15 (USC) was
used for molecular dynamics simulations and binding free energy calculations. Chimera (UCSF) and
PyMol Molecular Graphics software (Schrödinger) helped analyze details of protein–ligand interactions.
Online resources including protein data bank (http://www.rcsb.org/pdb/) and Enhanced National Cancer
Institute (NCI) database (https://cactus.nci.nih.gov/ncidb2.2/) were utilized to perform this study.
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5.2. Protein Refinement and Compound Database Preparation
Protein data bank (PDB) files (PDB ID: 5GJB, 1.7 Å X-ray resolution; PDB ID: 5GJC, 2.2 Å X-ray
resolution; PDB ID: 5JMT, 1.8 Å X-ray resolution) of ZIKV NS3 crystal structures were retrieved from
PDB database. All water molecules were removed and polar hydrogen atoms were assigned. After
that, protein structures were analyzed using the Protein Structure Preparation Tool in SYBYL-X 2.1.1.
Explicit hydrogen, disulfide bonds, and charges were assigned wherever missing, and side-chain
amides were fixed. NCI diversity set was downloaded from NCI compound database. 3D structures
were generated by SYBYL-X 2.1.1 and essential hydrogen atoms were added. Molecular minimization
was applied with the Gasteiger–Huckel charge and a distance-dependent dielectric function (dielectric
constant = 1.00), energy gradient of 0.001 Kcal/mol and maximum iterations of 2000 of Merck Molecular
Force Field 94 (MMFF94) method.
5.3. Virtual Screening using Surflex-Dock
Molecular docking studies were carried out on SYBYL-X 2.1.1 to screen potential binding candidate
compounds. Surflex-Dock (SFXC) algorithm serves as an automatic molecular docking program using
an empirical scoring function and a patented searching engine [52]. A negative-phase “protomol”
with a threshold of 0.50 and bloat set to 0 Å was generated for each protein structure. During docking
process, the maximum number of poses per ligand was set to 20. Other parameters were established
using default values. After docking, minimized ligand poses and their rankings were returned.
Consensus scores (C_Scores), representing an overall of Dock_Scores, PMF_Scores, Gold_Scores, and
Chem_Scores were provided for ranking the binding affinity of ligands to the receptor (SYBYL C_Score
module = Dock_Score + PMF_Score + Gold_Score + Chem_Score). Crash represented the degree of
inappropriate penetration into the protein as well as self-clashing of ligands.
5.4. In silico Molecular Interaction Analysis
Predicted binding poses of in vitro validated compounds were implemented using flexible
protein–ligand docking simulations on SYBYL-X 2.1.1 program. Hit compounds were docked to the
binding pockets with an acceptable target flexibility. Hydrogen and heavy atoms around binding sites
of protein target were able to change molecular coordinates. Amino acid interactions of the docked
molecules were analyzed by Chimera and PyMol.
5.5. Molecular Dynamics Simulation
Molecular dynamics (MD) simulation of docking complexes was performed using polarizable
ENZYMIX force field in MOLARIS package version 9.15. All MD simulations were completed using
spherical boundary conditions with a sphere of 18 Å radius solvated with water molecules subject to
the standard MOLARIS surface-constraint all-atom solvent (SCAAS) boundary conditions and the
local reaction field (LRF) long-range treatment, surrounded by 2 Å radius with Langevin dipole surface
embedded in a bulk continuum. The C atom near the geometric center of the ligand is defined as
the center of the simulations sphere. Each structure was relaxed by 3.0 ns MD simulation by being
gradually heated to a target temperature of 300 K with a step size of 1.0 fs.
5.6. Ab Initio Binding Free Energy Calculation
Binding free energy calculations were performed using the POLARIS module in MOLARIS
package version 9.15 [16]. All binding free energies were calculated using the Protein Dipole Langevin
Dipole (PDLD) method within its semimacroscopic-linear response approximation (PDLD/S-LRA)
with the LIE nonpolar term (PDLD/S-LRA/β). The MD runs were performed with the SCAAS spherical
boundary condition and the local reaction field (LRF) long-range treatment [16]. The PDLD/S-LRA
calculations involved a replacement of the SCAAS water molecules by Langevin Dipoles and the results
were averaged over 20 configurations. The simulations were performed following the previously
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reported procedure including relaxation dynamics of 90.0 ps, dynamics in water for 24.0 ps, and
dynamics in the protein for 24.0 ps with a step size of 1.0 fs [16].
∆GPDLD/S−LRA/βbind = ∆G
elec/PDLD/S−LRA
bind + β
[〈
Upvdw,l
〉
l
−
〈
Uwvdw,l
〉
l
]
5.7. Cell Culture and Compounds Preparation
BHK-21 cells (Baby Hamster Syrian Kidney-21) and Vero cells (African Green Monkey kidney)
were recovered and cultured using MEM Alpha Medium (HyClone, Logan, UT, USA) supplemented
with 10% fetal bovine serum (FBS) (Gibco, Grand Island, NY, USA), 100 IU penicillin, 0.1 mg/mL
streptomycin, and 1% HEPES at 37 ◦C in a 5% CO2 humidified environment. Compounds selected
from the top-scoring list were ordered from NCI compound library. All compounds in powder were
dissolved in DMSO as 10mM stock solutions, analyzed by NMR and mass spectrometry, and stored at
−80 ◦C for further dilution.
5.8. Virus Preparation and in Vitro Infection Assay
A Cambodian clinical ZIKA virus strain FSS13025 (GenBank: KU955593.1) was originally obtained
from a 3-year-old patient in 2010 [53]. Original viral stocks were then amplified in Vero cell lines
and titrated using quantitative RT-PCR and plaque assays. For infections, freshly cultured Vero or
BHK-21 cells were diluted into 1 × 106 cells/mL with PBS buffer. Then, 24-well flat-bottomed plates
were incubated at 37 ◦C in 5% CO2 and one milliliter of cell solutions was inoculated to each well and
cultured overnight with culture medium. After that, cells were infected by ZIKV at a MOI of 0.01 for
2 h. For mock infections, an equal volume of culture medium was used. Cells were incubated at 37 ◦C
in 5% CO2 for 72–120 h after infection.
5.9. Virus Plaque Reduction Assay
BHK-21 cells were diluted into 1 × 106 cells/mL and cultured overnight with BHK-21 medium as
described above. ZIKV at a MOI of 0.01 was added to each well and infected BHK-21 cells for 2 h.
For mock infections, an equal volume of culture medium was used. After that, cells were infected by
ZIKV at a MOI of 0.01 for 2 h. For mock infections, an equal volume of culture medium was used. After
that, cells were washed by PBS twice and 1 mL of fresh medium was added respectively with each
candidate antiviral compound at concentrations of 10 and 20 µM for Compound 1 and 50 and 100 µM
for Compound 2. Cells were incubated at 37 ◦C in 5% CO2 for 120 h after infection. To fix the cells,
10% formaldehyde solution was added to each well for 30 minutes. After fixing, formaldehyde was
discarded, and the cells were covered with a minimal amount of crystal violet solution for 1.5 h. Then,
crystal violet stain was gently washed off with water. The plaques were presented for further analysis.
The percentage of plaque inhibition to the virus control group of each compound was evaluated:
Inhibitory activity = (1 − number of plaques produced with candidate compounds/number of plaques
produced without candidate compounds) %.
5.10. Cytopathic Effect Inhibition Assay
The IC50 values of primary hit compounds were determined by cytopathic effect inhibition assay.
BHK-21 cells were cultured and infected as described above. Each primary hit antiviral compound
was added at a gradient concentration. IFN-α at a concentration of 20 IU served as positive control.
After 120 h, inhibition of cytopathic effects was assessed using a Cell Titer 96® Cell Proliferation
Assay (Promega Corporation, WI, USA) according to manufacturer’s instructions. Cell Titer-Blue
reagent was added and incubated for 2 h while viable cells reduced resazurin into resorufin. The
amount of resorufin produced was determined at λexcitation 560 nm and λemission 590 nm fluorescence
determination using a spectrophotometric microplate reader (Bio-Rad, Hercules, CA, USA).
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5.11. Time-of-Drug-Addition Assay
Time-of-addition experiment was conducted to explore which stage of the viral life cycle is affected
by hit compounds. BHK-21 cells were cultured and infected as described above. Compound 1 at a
concentration of 20 µM and Compound 2 at a concentration of 50 µM and was respectively added to
the assay medium at 2 h prior to infection (pre-treatment), at 0 (at the time of infection) to 2 hpi, or at 0,
2, 4, 8, 16, 32, 48, and 72 hpi. At 120 hpi, inhibition of cytopathic effects was assessed using a Cell Titer
96® Cell Proliferation Assay as described above.
5.12. Cytotoxicity Assay
Cytotoxicity of lead compounds against BHK-21, SupT-1 (Human lymphoma) as well as HEK293T
(Human embryonic kidney) cell lines were evaluated by Cell Titer-Blue viability assay as well. BHK-21
cells were seeded in a 96-well plate and cultured as described above. SupT-1 and HEK293T cells were
cultured respectively in RPMI-1640 Medium and Dulbecco’s Modified Eagle’s Medium (DMEM) instead
of MEM Alpha Medium. Compound solutions under a gradient concentration same as the inhibition
assay were added. Cells were incubated for 120 h, followed by addition of Cell Titer-Blue reagent to
each well and further incubated for 2 h according to manufacturer’s instructions. Determination of cell
viability was the same as described above.
5.13. Statistical Analysis
Biological assays were performed in triplicate and data were analyzed in Microsoft Excel and
plotted in GraphPad Prism 7 (GraphPad Software Inc., CA, USA). Average values were expressed
as mean ± SD or SEM, n ≥ 3. The results of Virus plaque reduction assay were representatives of
three independent experiments. A p-value less than 0.05 was considered statistically significant.
* p-value < 0.05, ** p-value < 0.005, *** p-value < 0.0005.
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NS3HEL non-structural protein 3 helicase;
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